Senseonics Holdings, Inc. is a Germantown-based medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.
On Friday, the company announced FDA approval of the world’s first and only long-term implantable continuous glucose monitoring system. Per the release, “it now offers patients exceptional accuracy for 6 months.”